Pittsburgh, PA – In a Nature Metabolism paper published today, researchers from the University of Pittsburgh detail a potential new target and a small-molecule drug candidate for treating Barth syndrome, a rare, life-threatening and currently incurable genetic disease with devastating consequences. Barth syndrome affects about 1 in every 300,000 to...
treatment News
Utrecht, Netherlands – The Organoid Group (Hubrecht Institute) and the Rare Cancers Genomics Team (IARC/WHO) found a way to grow samples of different types of neuroendocrine tumors (NETs) in the lab. While generating their new model, the researchers discovered that some pulmonary NETs need the protein EGF to be able...
NASHVILLE, Tenn. – A potential schizophrenia treatment discovered through the Warren Center for Neuroscience Drug Discovery has been cleared by the U.S. Food and Drug Administration for use in phase 1 clinical trials—the third WCNDD therapeutic to reach that benchmark. The drug is an allosteric modulator that works through a...
BIRMINGHAM, Ala. – It has been uncertain how Mycobacterium tuberculosis deflects the immune response in humans, though evidence has pointed to host immunometabolism — the intrinsic link between metabolism in immune cells and their immune function. The pathogen M. tuberculosis is known to disrupt a metabolic pathway called glycolysis in...
GERMANTOWN, Md. – Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the first patient has been dosed in the Phase I study of PRGN-2012, a first-in-class, investigational off-the-shelf (OTS) AdenoVerse™ immunotherapy in adult patients with recurrent respiratory...
GERMANTOWN, Md., March 18, 2021 — Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for PRGN-2012, a first-in-class, investigational off-the-shelf (OTS)...
Beijing, China – Glioblastoma (GBM) is the most common and aggressive malignant brain tumor in adults and is poorly controlled. Previous studies have shown that both macrophages and angiogenesis play significant roles in GBM progression, and co-targeting of CSF1R and VEGFR is likely to be an effective strategy for GBM...
Boston, MA — To help prevent preeclampsia and preterm birth—common complications in pregnancy that can be fatal to women and newborns—low-dose calcium supplementation (equivalent to one 500-milligram pill per day) may be as effective as the World Health Organization (WHO)’s recommended high-dose calcium supplementation (equivalent to three 500-milligram pills taken...
Despite taking medication, many epileptic children still suffer from associated seizures. Now Saudi Arabian researchers might have undertaken the first steps to change this. Epileptic seizures are abnormal electrical discharges in the brain which are usually accompanied by sudden brief episodes of altered or diminished consciousness or convulsions. These do...
LAGUNA HILLS, Calif. — PreludeDx, a leader in precision diagnostics, has unveiled data from an analysis of over 700 early-stage invasive breast cancer patients for AidaBreast™ – a novel biosignature that predicts 10-year recurrence rate and radiation therapy (RT) benefit – at the 41st Annual Miami Breast Cancer Conference (MBCC)....